Back to Search
JAMES ROBERTSON, M.D.
M.D.
Otolaryngology Physician
NPI: 1578551354Individual
Specialties, Licenses & Credentials
Otolaryngology PhysicianPrimary
Otolaryngology
Code: 207Y00000X
35032598(OH)
Research & Publications (20)
Relevance of botulinum toxin injection and nerve block of rectus femoris to kinematic and functional parameters of stiff knee gait in hemiplegic adults.
PMID 18771925·Gait Posture·2009
8-other
Deficiency of LRP8 in mice is associated with altered platelet function and prolonged time for in vivo thrombosis.
PMID 18706682·Thromb Res·2009
7-preclinical
One hundred days or more bridged on a ventricular assist device and effects on outcomes following heart transplantation.
PMID 18539472·Eur J Cardiothorac Surg·2008
8-other
Early failure of bioprostheses caused by adhesion of preserved leaflets after chordal-sparing mitral valve replacement.
PMID 18455607·J Thorac Cardiovasc Surg·2008
5-case
Effects of fulvestrant 250mg in premenopausal women with oestrogen receptor-positive primary breast cancer.
PMID 17064888·Eur J Cancer·2007
3-trial
Planned versus provisional use of glycoprotein IIb/IIIa inhibitors in smokers undergoing percutaneous coronary intervention.
PMID 16765113·Am J Cardiol·2006
2-rct
Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy.
PMID 16652323·Clin Infect Dis·2006
8-other
Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant.
PMID 15986127·Breast Cancer Res Treat·2005
4-observational
Endocrine treatment options for advanced breast cancer--the role of fulvestrant.
PMID 15691633·Eur J Cancer·2005
4-observational
Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.
PMID 15541579·Cancer Treat Rev·2004
6-review
The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women.
PMID 12706354·Eur J Cancer·2003
6-review
Equivalent single-dose pharmacokinetics of two different dosing methods of prolonged-release fulvestrant ('Faslodex') in postmenopausal women with advanced breast cancer.
PMID 12879276·Cancer Chemother Pharmacol·2003
3-trial
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
PMID 12872340·Cancer·2003
3-trial
Pharmacokinetics of a single dose of fulvestrant prolonged-release intramuscular injection in postmenopausal women awaiting surgery for primary breast cancer.
PMID 12867220·Clin Ther·2003
3-trial
The Internet: the future source of information for professionals in the field of breast cancer.
PMID 14965702·Breast·2002
8-other
Caspase-2 acts upstream of mitochondria to promote cytochrome c release during etoposide-induced apoptosis.
PMID 12065594·J Biol Chem·2002
8-other
Faslodex (ICI 182, 780), a novel estrogen receptor downregulator--future possibilities in breast cancer.
PMID 11850227·J Steroid Biochem Mol Biol·2001
4-observational
Molecular mechanisms of apoptosis induced by cytotoxic chemicals.
PMID 11055838·Crit Rev Toxicol·2000
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1110 W MAIN CROSS ST
FINDLAY, OH 45840 - Phone
- (419) 424-1393
Quick Facts
- NPI
- 1578551354
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile